ResMed

D

Quotes are delayed by 15 minutes

ResMed (RMD) trades at 235.26 USD, -1.69% today. Over the last 52 weeks it has traded between 180.27 and 277.67.

ResMed trades on NYSE under the ticker RMD.

ResMed's share price has fallen 5.8% over the last 12 months. Since the start of the year it is -3.2%.

$1,000 invested in ResMed on 4 November 2016 would be worth $4,577 on 6 November 2026, with its dividends reinvested: 16.4% a year. The same in SPY (the S&P 500) would be $4,128, in QQQ (the Nasdaq 100) $6,186.

ResMed's beta is 0.76: its price has moved less than the US market as a whole.

At today's price ResMed is worth 33.09B USD. Market cap history

ResMed's P/E of 21.4 is near the bottom of its 5-year range (17.6 to 75.4, median 28.6). Analysts expect slower growth than in recent years, so the low P/E may be deserved. At its usual P/E (28.1 × EPS of 10.48), ResMed's fair value is 294.55; the price, 235.26, is ⁦20.1%⁩ below it. The EPS is without 0.51 a share of one-off gains in its other income, which the business does not repeat. P/E history

ResMed earned 10.99 a share over the last twelve months. At today's price its shares trade at 21.4 times those earnings. EPS history

In Q1 FY2027, reported on 29 October 2026, revenue was 1.41B USD and net income 418.41M USD. Revenue was +5.9% on the same quarter a year before. EPS of 2.91 beat the 2.69 analysts expected. Every earnings report

ResMed reports its next results on 28 January 2027. Earnings and estimates

The shares moved -9.2% on the trading day after its Q1 FY2027 report on 29 October 2026. Every report and its move

Yes: 2.64 USD a share a year at its current rate, a 1.12% yield at today's price. Dividend history and dates

The next ex-dividend date is 11 November 2026, with the dividend paid on 17 December 2026: shares bought before the ex-dividend date receive it. Every dividend and its dates

3 of the 11 firms that rate ResMed say buy, 8 hold and 0 sell. Their average 12-month price target is 246.89. Forecast and price targets

ResMed spent 1.99B USD buying back its own shares over the last twelve months. Its diluted share count fell 1.6% in fiscal year 2026. Buyback history

Over the last twelve months ResMed's insiders made 31 open-market sales of 91,974 shares for 21.62M USD, and 0 purchases. The CEO, Michael J. Farrell, sold 62,912 of them. Every insider trade

ResMed has split its stock 4 times: 2-for-1 (1998), 2-for-1 (2000), 2-for-1 (2005), 2-for-1 (2010). The last was a 2-for-1 split on 31 August 2010. A split adds shares without changing what the company is worth.

ResMed is in the Healthcare sector, in the Medical - Instruments & Supplies industry. Company profile

Yes. ResMed stock is halal by the AAOIFI Shariah screen, on its latest figures: its business (Medical - Instruments & Supplies) is not an excluded activity, its debt is 1.8% of its market value and its cash and interest-bearing investments 3.1% (the limit is 30% each), and its interest income is 0.0% of its revenue (the limit is 5%). Scholars and screening methods differ.

Through a broker that trades on NYSE: open and fund an account, search for RMD and place an order. Arincen compares regulated brokers in its broker reviews.